Pacira Biosciences Inc Quick Ratio (PCRX) starting from the second quarter 2026 to second quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Pacira Biosciences inc   (NASDAQ: PCRX)

Pacira Biosciences Inc 's Quick Ratio

PCRX's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Pacira Biosciences Inc 's Cash & cash equivalent grew by 24.16 % in the Q2 2026 sequentially, faster than Current Liabilities, this led to improvement in Pacira Biosciences Inc 's Quick Ratio to 2.06, Quick Ratio remained below Pacira Biosciences inc average.

Within Major Pharmaceutical Preparations industry 287 other companies have achieved higher Quick Ratio than Pacira Biosciences Inc in second quarter 2026. While Quick Ratio total ranking in the second quarter 2026 has deteriorated compared to the prior quarter from 1141 to 1233.

Explain Quick Ratio?
How much Cash & cash equivalents PCRX´s has?
What are PCRX´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

PCRX Quick Ratio (Jun 30 2026)
Q2		 (Mar 31 2026)
Q1		 (Dec 31 2025)
Q4		 (Sep 30 2025)
Q3		 (Jun 30 2025)
Q2
Y / Y Current Liabilities Change -61.04 % -65.44 % -59.09 % -65.05 % 237.86 %
Y / Y Cash & cash equivalent Change -43.7 % -59.04 % -50.8 % -45.72 % 10.3 %
Quick Ratio MRQ 2.06 1.86 1.88 2.3 1.42
PCRX's Total Ranking # 1233 # 1141 # 644 # 869 # 1177
Seq. Current Liabilities Change 12.16 % -14.2 % 18.41 % -65.81 % -0.5 %
Seq. Cash & cash equivalent Change 24.16 % -15.2 % -3.21 % -44.75 % -9.68 %



Quick Ratio second quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 288
Healthcare Sector # 497
Overall Market # 1233


Quick Ratio Statistics
High Average Low
9.31 3.16 0.54
(Mar 31 2013)   (Mar 31 2014)




Financial Statements
Pacira Biosciences Inc 's Current Liabilities $ 122 Millions Visit PCRX's Balance sheet
Pacira Biosciences Inc 's Cash & cash equivalent $ 251 Millions Visit PCRX's Balance sheet
Source of PCRX's Sales Visit PCRX's Sales by Geography


Cumulative Pacira Biosciences Inc 's Quick Ratio

PCRX's Quick Ratio for the trailling 12 Months

PCRX Quick Ratio

 (Jun 30 2026)
12 Months		 (Mar 31 2026)
12 Months		 (Dec 31 2025)
12 Months		 (Sep 30 2025)
12 Months		 (Jun 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth -62.65 % -35.94 % 7.39 % 76.46 % 227.95 %
Y / Y Cash & cash equivalent TTM Growth -50.05 % -38.31 % -14.64 % 3.35 % 34.37 %
Quick Ratio TTM 2.02 1.73 1.65 1.6 1.51
Total Ranking TTM # 3891 # 2923 # 2053 # 2865 # 2976
Seq. Current Liabilities TTM Growth -29.15 % -23.9 % -17.53 % -16.02 % 21.54 %
Seq. Cash & cash equivalent TTM Growth -17.2 % -20.46 % -14.74 % -11.05 % 2.27 %

Quick ratio ranking by company, industry and sector >> Back to PCRX Financial Strength Comparisons >> Go to Compare PCRX Quick Ratio to its Competitors

On the trailing twelve months basis Current Liabilities decreased faster than Pacira Biosciences Inc 's average Cash & cash equivalent, this led to increase in in Pacira Biosciences Inc 's Quick Ratio to 2.02, Quick Ratio remained below PCRX average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 430 other companies have achieved higher Quick Ratio than Pacira Biosciences Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2026 from 2923 to 3891.

Explain Quick Ratio?
How much Cash & cash equivalents PCRX´s has?
What are PCRX´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 431
Healthcare Sector # 885
Within the Market # 3891


trailing twelve months Quick Ratio Statistics
High Average Low
6.84 2.78 0.79
(Mar 31 2019)   (Jun 30 2014)




Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Major Pharmaceutical Preparations Industry Quick RatioJun 30 2026 MRQ Cash & cash equivalentJun 30 2026 MRQ Current Liabilities
Adial Pharmaceuticals Inc   5.51 $ 28.200  Millions$ 5.121  Millions
Corbus Pharmaceuticals Holdings Inc   5.49 $ 117.941  Millions$ 21.483  Millions
Bio Green Med Solution Inc   5.48 $ 3.790  Millions$ 0.692  Millions
Arrowhead Pharmaceuticals Inc   5.47 $ 1,551.301  Millions$ 283.346  Millions
Context Therapeutics Inc   5.45 $ 42.990  Millions$ 7.885  Millions
Annexon Inc   5.44 $ 209.200  Millions$ 38.482  Millions
Mereo Biopharma Group Plc  5.37 $ 30.506  Millions$ 5.677  Millions
Cns Pharmaceuticals Inc   5.35 $ 19.985  Millions$ 3.738  Millions
Neurogene Inc   5.23 $ 112.485  Millions$ 21.505  Millions
Lexaria Bioscience Corp   5.20 $ 3.642  Millions$ 0.701  Millions
Barinthus Biotherapeutics Plc  5.19 $ 59.295  Millions$ 11.423  Millions
Lite Strategy Inc   5.15 $ 5.706  Millions$ 1.109  Millions
Immuneering Corporation  5.14 $ 41.731  Millions$ 8.116  Millions
Lyell Immunopharma Inc   5.12 $ 204.102  Millions$ 39.867  Millions
Altimmune inc   5.04 $ 63.008  Millions$ 12.501  Millions
Rani Therapeutics Holdings Inc   5.02 $ 53.391  Millions$ 10.638  Millions
Phio Pharmaceuticals Corp  4.99 $ 12.996  Millions$ 2.606  Millions
Immunic Inc   4.96 $ 155.098  Millions$ 31.260  Millions
Silo Pharma Inc  4.90 $ 5.227  Millions$ 1.066  Millions
Atossa Therapeutics Inc   4.81 $ 26.204  Millions$ 5.451  Millions
Calcimedica Inc   4.71 $ 18.600  Millions$ 3.950  Millions
Kala Bio inc   4.70 $ 7.229  Millions$ 1.538  Millions
Septerna Inc   4.69 $ 372.322  Millions$ 79.316  Millions
Viking Therapeutics Inc   4.57 $ 501.663  Millions$ 109.656  Millions
Camp4 Therapeutics Corporation  4.51 $ 86.398  Millions$ 19.142  Millions
Rein Therapeutics Inc   4.49 $ 43.627  Millions$ 9.709  Millions
Quantum Cyber N v   4.46 $ 13.415  Millions$ 3.005  Millions
Maia Biotechnology Inc   4.41 $ 27.596  Millions$ 6.258  Millions
Azitra Inc   4.40 $ 6.728  Millions$ 1.531  Millions
Cypherpunk Technologies Inc   4.39 $ 7.624  Millions$ 1.737  Millions

Date modified: 2026-09-26T06:58:04+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.